On June 26, HJ Science-B declined 8.41% in regular trading, trading at HK$43.92 per share, with turnover of HK$6.28 million. The stock continues to face selling pressure following its Hong Kong debut on June 23, when it closed down 56.89% from its IPO price of HK$81.80.

The company listed as a clinical-stage biotech under Chapter 18A with no approved products for commercial sale and no revenue from product sales. Despite its Hong Kong public offering being oversubscribed 2,007.6 times, the stock has failed to sustain momentum in secondary market trading. The most advanced pipeline is only in Phase II clinical trials, and the company reported a net loss of approximately RMB 202 million for the year ended December 2024. Net IPO proceeds of approximately HK$1.02 billion are intended primarily for clinical research and development activities.

HJ Science was co-founded by multiple PhDs and is primarily engaged in the research and development of innovative drugs targeting oncology, autoimmune diseases, and metabolic disorders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)